2. Search Result
Search Result
Results for "

CB1+receptor+antagonist

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15443
    AM251
    Maximum Cited Publications
    23 Publications Verification

    		 Cannabinoid Receptor Neurological Disease
    AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC50 of 39 nM [1] .
    AM251
  • HY-B1161A
    S-Methoprene
    2 Publications Verification

    (+)-Methoprene; (7S)-Methoprene

    		 Environmental Pollutants Cannabinoid Receptor Others
    S-Methoprene is an insect juvenile hormone analog and effective insecticide that blocks the transition from pupa to adult. S-Methoprene is also a CB(1) receptor ligand and inhibits the binding of the CB1 receptor antagonist [ 3H]CP-55940 to the CB1 receptor (IC50: 19.31 μM) [1] .
    S-Methoprene
  • HY-13505
    AM281
    1 Publications Verification

    		 Cannabinoid Receptor Neurological Disease
    AM281 is a selective CB1 receptor antagonist with an IC50 of 9.91 nM. AM281 inhibits CB2 receptor with an IC50 of 13000 nM [1].
    AM281
  • HY-14791A
    (±)-Ibipinabant
    1 Publications Verification

    (±)-SLV319; (±)-BMS-646256

    		 Cannabinoid Receptor Metabolic Disease
    (±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC50 of 22 nM.
    (±)-Ibipinabant
  • HY-110206
    AM6545

    		Cannabinoid Receptor Metabolic Disease
    AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (Ki=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications [1] .
    AM6545
  • HY-14788
    Drinabant

    AVE1625

    		 Cannabinoid Receptor Metabolic Disease
    Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R [1].
    Drinabant
  • HY-103327
    MJ15

    		Cannabinoid Receptor Metabolic Disease
    MJ15 is a potent and selective CB1 receptor antagonist with a Ki of 27.2 pM and an IC50 of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice [1].
    MJ15
  • HY-N6097
    Amauromine

    		Cannabinoid Receptor Neurological Disease
    Amauromine is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist with Ki and Kb values of 178 nM and 66.6 nM, respectively [1].
    Amauromine
  • HY-12606
    BMS-812204

    		Cannabinoid Receptor Metabolic Disease
    BMS-812204 is a highly selective CB-1 receptor antagonist. BMS-812204 is promising for research of obesity and metabolic disorders [1].
    BMS-812204
  • HY-121827
    LH21
    1 Publications Verification

    		 Cannabinoid Receptor Metabolic Disease
    LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor [1].
    LH21
  • HY-133533
    O-2050

    		Cannabinoid Receptor Neurological Disease
    O-2050 is a high affinity cannabinoid CB1 receptor antagonist with a Ki of 2.5 nM. O-2050 inhibits cannabinoid CB2 receptor (Ki=0.2 nM). O-2050 can cause locomotor stimulation in mice [1].
    O-2050
  • HY-103336
    Tocrifluor 1117

    T1117

    		 GPR55 Cannabinoid Receptor Cardiovascular Disease
    Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid CB1 receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm) [1] .
    Tocrifluor 1117
  • HY-110020
    rel-O-2050

    		Cannabinoid Receptor Metabolic Disease
    rel-O-2050 (Compound O-2050) is a neutral cannabinoid CB1 receptor antagonist. rel-O-2050 also decreases food intake in mice [1].
    rel-O-2050
  • HY-13505R
    AM281 (Standard)

    		Cannabinoid Receptor Neurological Disease
    AM281 (Standard) is the analytical standard of AM281. This product is intended for research and analytical applications. AM281 is a selective CB1 receptor antagonist with an IC50 of 9.91 nM. AM281 inhibits CB2 receptor with an IC50 of 13000 nM [1].
    AM281 (Standard)
  • HY-15443R
    AM251 (Standard)

    		Cannabinoid Receptor Neurological Disease
    AM251 (Standard) is the analytical standard of AM251. This product is intended for research and analytical applications. AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC50 of 39 nM [1] .
    AM251 (Standard)
  • HY-139230
    OLHHA

    		Cannabinoid Receptor PPAR Metabolic Disease
    OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) [1] .
    OLHHA
  • HY-118056
    ABD459

    		Cannabinoid Receptor
    ABD459 is a CB1 receptor antagonist with significant effects on regulating food intake and sleep-wake cycles. ABD459 completely displaces CB1 agonist CP99540 (Ki = 8.6 nM) and antagonizes CP55940-induced GTPγS binding (KB = 7.7 nM). ABD459 may specifically modulate endogenous cannabinoid release through cholinergic activity and plays a role in attention and arousal regulation. ABD459 is suitable for research in neurological disorders [1].
    ABD459
  • HY-14791AR
    (±)-Ibipinabant (Standard)

    (±)-SLV319 (Standard); (±)-BMS-646256 (Standard)

    		 Cannabinoid Receptor Reference Standards Metabolic Disease
    (±)-Ibipinabant (Standard) is the analytical standard of (±)-Ibipinabant. This product is intended for research and analytical applications. (±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC50 of 22 nM.
    (±)-Ibipinabant (Standard)
  • HY-103327R
    MJ15 (Standard)

    		Reference Standards Cannabinoid Receptor Metabolic Disease
    MJ15 (Standard) is the analytical standard of MJ15 (HY-103327). This product is intended for research and analytical applications. MJ15 is a potent and selective CB1 receptor antagonist with a Ki of 27.2 pM and an IC50 of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice [1].
    MJ15 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: